Project: BEAM Alliance

Acronym BEAM Alliance (Reference Number: JPIAMR_2016_N007)
Duration 01/01/2017 - 31/12/2017
Project Topic The growing risk of multi-drug resistant bacteria is a global public health crisis recognized by many governments; therefore, to combat the spread of resistant-bacteria and superbugs, new antibiotics, or alternative therapies must be developed. However, the financial attraction for R&D investment from large pharmaceutical companies is lacking, therefore, innovation in this therapeutic area is predominantly steered by small and medium pharma companies. To tackle the obstacle that superbugs present to society expeditiously, new policies and R&D incentives are needed to stimulate development in the EU. As an answer to this urgent need, we have formed the BEAM Alliance. The BEAM Alliance represents 50 European biopharmaceutical companies (small and medium size (SME)) from 12 European countries involved in developing innovative products to combat antimicrobial resistance in humans and beyond. The Working Group objective is to produce a new position paper regarding establishment of economic incentives in order to better sustain the innovation efforts of small and medium biopharmaceutical companies. The Working Group will collaborate with the existing community of stakeholders dedicated to implementing tangible strategies, including the EC DG SANTE, the UK AMR Review, WHO and the DRIVE-AB consortium. The BEAM Alliance Working Group should thus allow for expression of a unique and unprecedented opinion from the European SMEs perspective.
Website visit project website
Network JPI AMR
Call 4th Joint Call: Research Networking Programmes

Project partner

Number Name Role Country
1 DaVolterra Coordinator France
2 ABAC Therapeutics Observer Spain
3 Abgentis Observer United Kingdom
4 Absynth Biologics Observer United Kingdom
5 Adenium Biotech Observer Denmark
6 AiCuris Anti-infective Cures GmbH Observer Germany
7 Alaxia Observer France
8 Allecra Observer Germany
9 Antabio SAS Observer France
10 AntibioTx ApS Observer Denmark
11 Arsanis Biosciences GmbH Observer Austria
12 Auspherix Observer United Kingdom
13 Basilea Pharmaceutica International Ltd. Observer Switzerland
14 BioFilm Control Observer France
15 BioVersys AG Observer Switzerland
16 Biovertis Observer Austria
17 Blueberry Therapeutics Observer United Kingdom
18 Cantab Anti-infectives Observer United Kingdom
19 Deinobiotics Observer France
20 Destiny Pharma, Ltd. Observer United Kingdom
21 Discuva Observer United Kingdom
22 Eligo Bioscience Observer France
23 Evotec Observer United Kingdom
24 FAB Pharma Observer France
25 Helperby Observer United Kingdom
26 IMMT Observer Slovenia
27 Immunsystem AB Observer Sweden
28 Lamellar Biomedical Observer United Kingdom
29 Maat Pharma Observer France
30 MGB Biopharma Limited Observer United Kingdom
31 Mutabilis SAS Observer France
32 NAICONS Srl Observer Italy
33 Northern Antibiotics Ltd Observer Finland
34 Nosopharm Observer France
35 Novabiotics Ltd Observer United Kingdom
36 OLMIX Observer France
37 Pherecydes Pharma Observer France
38 Phico Therapeutics Observer United Kingdom
39 Polyphor Ltd Observer Switzerland
40 Procarta Biosystem Observer United Kingdom
41 Redx Pharma Observer United Kingdom
42 Setlance Observer Italy
43 Setubio Observer France
44 Synamp Pharmaceuticals Observer Netherlands
45 TechnoPhage SA Observer Portugal
46 Vibiosphen Observer France
47 Micreos Observer Netherlands
48 Nabriva Therapeutics Observer Austria
49 Centauri Therapeutics Observer United Kingdom
50 Neem Biotech Observer United Kingdom